Patients who took certain drugs to combat type 2 diabetes proved less likely to develop dementia, according to research that suggests brain disorders could be tackled with therapies devised for other uses.
The study of more than 200,000 people found that rates of Alzheimer’s disease for those who took inhibitors for sodium-glucose cotransporter-2 (SGLT-2), to lower their blood sugar, were more than a third lower than for those on another anti-diabetes medication.
While the observational survey conducted in South Korea does not demonstrate a causal link between SGLT-2 inhibitors and prevention of dementia, more extensive trials of some diabetes drugs such as Novo Nordisk’s Ozempic for similar uses are already under way.
您已閱讀19%（729字），剩餘81%（3137字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。